Revenue grew 2.6% at constant currency in H1 2026, led by Biopharma and strong IG demand, with adjusted EBITDA up 2.4% and free cash flow improving by EUR 103 million year-over-year. Albumin in China stabilized, diagnostics repositioning advanced, and the company remains on track for its 2026 guida…
Revenue and profit grew in H1 2026, led by Biopharma and strong IG demand, with adjusted EBITDA and free cash flow improving year-over-year. Albumin in China is stabilizing, diagnostics is advancing post-JV, and plasma sourcing in Egypt is ramping up, supporting 2026 guidance.Based on Grifols, S.A…
Revenue grew 2.6% at constant currency to €3,574m, with adjusted EBITDA up 2.4% and group profit rising 28.7% year-over-year. Biopharma led growth, while refinancing strengthened liquidity and leverage improved. H1 2026 results support full-year guidance.Original document: Grifols, S.A. Class A [GR…
Revenue grew 2.6% at constant currency to €3,574 million, driven by Biopharma, while adjusted EBITDA margin remained strong at 23.9%. Net profit rose to €227 million, supported by operational efficiency and lower financing costs after refinancing. Strategic initiatives included US plasma center clo…
Revenue grew 2.6% year-over-year to €3.57 billion, with net profit up 28.7% and adjusted EBITDA at €854 million. Biopharma led growth, especially in immunoglobulins, while Diagnostics repositioned for future expansion. Strong liquidity and successful refinancing support the 2026 outlook.Original do…
